EVMN
NYSE Evommune, Inc.$6.92 ↑ +0.00 (+0.00%) Trading Up from the previous close of $6.92, $0.36 below the day’s high of $7.28
- YTD change
- -59.58%
- vs 20-day SMA
- -29.18%
- vs 200-day SMA
- -63.57%
Price ranges
Price & Performance
-16.80 (-70.83%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 79.2% away from all-time highs of $33.20
- EVMN is down 60% since the beginning of the year
- EVMN is down 66% over the past 12 months
- EVMN is down 45% over the past 1 month
- 14% of all EVMN investors are betting against EVMN
- Number of investors short EVMN has gone down 34% versus last month
EVMN reads poor: price sits below both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is -65.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.05
- Last 5 days
- -21.36%
- vs 8-day SMA
- -18.43%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.